Leptos Biomedical

About Leptos Biomedical

Leptos Biomedical was a medical device company focused on creating a neuromodulation therapy to address obesity. The firm's core technology centered on a device that delivered electrical stimulation to the splanchnic nerve, a key component of the autonomic nervous system. This approach was designed to manipulate the signals transmitted between the brain and the stomach.

The company's strategy was to activate the body's "fight-or-flight" response through nerve stimulation, which in turn would encourage the body to expend more energy and burn fat. This method differentiated it from other companies in the sector, such as EnteroMedics, which targeted the vagus nerve to suppress hunger signals. The business operated in the therapeutic devices market, with a focus on bariatric solutions.

Founded in the mid-2000s, Leptos Biomedical secured significant venture capital to fund its product development. The company raised at least $17.1 million from investors including Spray Venture Partners, Technology Partners, and Thomas, McNerney & Partners. A notable funding round was a Series A in August 2004 for $1.1 million. Despite its efforts and financial backing, the company ceased operations around February 2010. The shutdown was reportedly influenced by the challenging clinical trial outcomes faced by its competitor, EnteroMedics, which created a difficult environment for companies with similar technologies to secure further support and regulatory approval. Following its closure, the company's assets were reportedly acquired by St. Jude Medical.